{"id":3737,"date":"2019-01-04T14:38:01","date_gmt":"2019-01-04T20:38:01","guid":{"rendered":"https:\/\/ibio.org\/?p=3737"},"modified":"2019-06-24T14:39:58","modified_gmt":"2019-06-24T19:39:58","slug":"ibio-comments-to-administration-on-international-pricing-index-model","status":"publish","type":"post","link":"https:\/\/ibio.org\/ibio-comments-to-administration-on-international-pricing-index-model\/","title":{"rendered":"iBIO Comments to administration on International Pricing Index Model"},"content":{"rendered":"<p>At the end of 2018 iBIO submitted comments on the proposed International Pricing IndEx (IPI) Model for Medicare Part B medicines.<\/p>\n<p>Medicare Part B supports the sickest, most vulnerable Medicare patients and only accounts for a small fraction of all Medicare Spending.<\/p>\n<p>The Trump Administration through the Centers for Medicare &amp; Medicaid Services (CMS) is proposing the IPI Model, moving from a market-based payment formula for Part B drugs to one based on foreign prices.<\/p>\n<p>Here are a few of our concerns with the IPI model.<\/p>\n<ul>\n<li>Imports foreign price controls on American innovation, putting America\u2019s most vulnerable patients last and diminishing their hopes for a better future;<\/li>\n<li>Undermines a successful Medicare Part B program by introducing new middlemen between patients and the medicines they need; and<\/li>\n<li>Fails to properly consider patient benefit, quality of care, or the impact on all patients and health care providers.<\/li>\n<li>Chills investment and research in innovative treatment solutions as well as the economic growth generated by this sector in our state<\/li>\n<\/ul>\n<p>The comments highlighted our concerns and encouraged CMS to engaged in a in a revised discussion of proposals that focus on solutions that truly assist patients with reducing their out-of-pocket costs while maintaining and improving access to a full range of needed treatment options.<\/p>\n<p>Following the notice and comment period, CMS is considering issuing a proposed rule for the IPI in the spring of 2019, with a potential model start in spring 2020.<\/p>\n<div class=\"sfsi_Sicons\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>At the end of 2018 iBIO submitted comments on the proposed International Pricing IndEx (IPI) Model for Medicare Part B medicines. Medicare Part B supports the sickest, most vulnerable Medicare patients and only accounts for a small fraction of all Medicare Spending. The Trump Administration through the Centers for Medicare &amp; Medicaid Services (CMS) is [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[146],"tags":[],"class_list":["post-3737","post","type-post","status-publish","format-standard","hentry","category-policy-news"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/3737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=3737"}],"version-history":[{"count":0,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/3737\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=3737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=3737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=3737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}